Go to the list of all blogs
Niko Sharks's Avatar
published in Blogs
Jul 01, 2023

Acme United (ACU) Announces Dividend Payout for July 24, 2023: An Analysis

In a latest financial announcement, Acme United (ACU) - a renowned company in the industrial goods sector, has declared that it will pay a dividend of $0.14 per share with a record date of July 24, 2023. The ex-dividend date is set for June 30, 2023. This dividend distribution mirrors the last payout of $0.14 per share, which was dispensed on April 21, 2023.

In the investment world, dividends are seen as a key indicator of a company's financial health and its profitability. Companies that consistently pay dividends are generally considered financially stable, which can create investor confidence and attract potential shareholders.

The company's announcement also highlights key dates, namely the ex-dividend and the record date. It's worth noting these as they play a significant role in who receives the forthcoming dividend payment.

The ex-dividend date, scheduled for June 30, 2023, is particularly important for investors to keep in mind. This is the date after which any purchased stocks will not include the rights to the next dividend payment. Simply put, if an investor buys the stocks on or after the ex-dividend date, they will not receive the upcoming dividend. Instead, that dividend is 'repossessed' by the seller.

The record date (July 24, 2023) is the date by which you must officially own shares of Acme United to be entitled to the dividend. Any changes in stock ownership on or after this date do not affect the dividend payment.

The consistent dividend of $0.14 per share indicates Acme United's steady approach to returning capital to shareholders. This can be seen as a positive sign for investors, as it signals the company's strong cash position and its ability to generate consistent earnings.

It's worth noting that a stable and predictable dividend often hints at a company's underlying financial strength. However, investors should also look at other performance indicators and financial metrics to get a complete picture of the company's financial status.

Investors interested in purchasing Acme United shares with the aim of earning dividends should take action before the ex-dividend date of June 30, 2023. The consistent dividend payout indicates a positive cash flow status of the company, which could be a promising sign for prospective and current shareholders. However, every investment decision should be made after considering various factors, and dividends are just one aspect of the company's overall financial health.

As we move towards the record date, it will be interesting to monitor Acme United's performance and see if the company continues to maintain its dividend payout amid the dynamic market conditions.

Related Ticker: ACU

Aroon Indicator for ACU shows an upward move is likely

ACU's Aroon Indicator triggered a bullish signal on September 10, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 154 similar instances where the Aroon Indicator showed a similar pattern. In 112 of the 154 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 73%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 22, 2026. You may want to consider a long position or call options on ACU as a result. In 76 of 113 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.

Following a +1.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACU advanced for three days, in 161 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 70 cases where ACU's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 69%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 30 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. ACUโ€™s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.015) is normal, around the industry mean (18.044). P/E Ratio (26.790) is within average values for comparable stocks, (43.673). Projected Growth (PEG Ratio) (0.140) is also within normal values, averaging (1.518). Dividend Yield (0.010) settles around the average of (0.024) among similar stocks. P/S Ratio (1.207) is also within normal values, averaging (1.931).

The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Procter & Gamble Company (NYSE:PG), Colgate-Palmolive Company (NYSE:CL).

Industry description

Household/Personal Care companies sell products for home cleaning and/or personal hygiene and grooming purposes. Products of this industry include detergents, shampoos, soaps, cosmetics, fabric conditioners and infant care fragrances. Procter & Gamble, Unilever, Estee Lauder and Colgate-Palmolive are some of the biggest names in the business. A lot of the products become a necessary part of peopleโ€™s daily routine, and therefore the industry is relatively less vulnerable to macroeconomic downturns. At the same time, product quality, consumer safety, and ease of use are extremely critical factors for a company to survive competition and earn recognition in this industry.

Market Cap

The average market capitalization across the Household/Personal Care Industry is 23.45B. The market cap for tickers in the group ranges from 60.48K to 346.15B. PG holds the highest valuation in this group at 346.15B. The lowest valued company is EOSS at 60.48K.

High and low price notable news

The average weekly price growth across all stocks in the Household/Personal Care Industry was -2%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 7%. ODD experienced the highest price growth at 11%, while TANH experienced the biggest fall at -19%.

Volume

The average weekly volume growth across all stocks in the Household/Personal Care Industry was -3%. For the same stocks of the Industry, the average monthly volume growth was -17% and the average quarterly volume growth was -42%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 43
Price Growth Rating: 57
SMR Rating: 72
Profit Risk Rating: 90
Seasonality Score: 12 (-100 ... +100)
View a ticker or compare two or three
ACU
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a supplier of cutting devices, measuring and safety products to the school, home, office, hardware and industrial markets

Industry HouseholdPersonalCare

Industry
Tools And Hardware
Address
1 Waterview Drive
Phone
+1 203 254-6060
Employees
649
Web
https://www.acmeunited.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studioโ€”a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze โ€” but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 โ€” trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire โ€” literally and figuratively. With crude oil prices swinging 20โ€“30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas โ€“ E&P) AI Trading Agent โ€” a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated modelโ€”from discovery to commercializationโ€”drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
Acme United (ACU) Announces Dividend Payout for July 24, 2023: An Analysis